[Insight] Lotte’s Turnaround Is Best Understood Through the Movement of Capital

Lotte Group's latest financial results highlight a significant transformation in the company's strategic focus. The second quarter of 2026 saw revenue rise 4.0% to KRW 3.485 trillion, with operating profit soaring 121.2% to KRW 89.9 billion. Net income returned to positive territory, signaling a recovery across the group's operations.

However, this positive trend should not be viewed in isolation. The real change lies in the strategic reallocation of resources and capital from established businesses to emerging growth sectors. Central to this shift is Lotte Biologics' new manufacturing plant at the Songdo Bio Campus in Incheon, which is nearing completion and set to begin commercial production in 2027.

This plant, with a manufacturing capacity of 120,000 liters, represents a substantial investment of approximately KRW 1.4 trillion and will consolidate Lotte Biologics' production, quality, and business development functions.

Lotte's operations can be grouped into three distinct categories, each with its own timeline for profitability. Retail earnings fluctuate based on consumer demand and tourism, while the chemicals division operates on longer industrial cycles influenced by feedstock prices and global supply adjustments. The biologics sector, on the other hand, requires years of investment, regulatory approval, and technology development before generating significant revenue.

Lotte Shopping's department store business, a key part of its retail portfolio, showed a 9.2% year-on-year increase in revenue to KRW 891.2 billion, driven by higher spending from foreign tourists and strong fashion sales. Meanwhile, Lotte Mall West Lake Hanoi in Vietnam has maintained record operating profits for six consecutive quarters, demonstrating the success of the company's overseas expansion strategy.

The chemicals division, however, presents a more challenging picture. While its basic chemicals business has returned to profitability, its advanced materials division is showing more promise, generating higher operating profits than the company's overall profit. This indicates that a sustained recovery in the chemicals sector will depend on a shift towards more stable, higher-margin products.

Lotte Chemical's focus will now be on reducing exposure to low-margin commodity products and expanding its advanced materials and other profitable business areas.

The Songdo Biologics plant is a critical milestone in this transformation, but its full value will only be realized once it passes regulatory inspections, demonstrates consistent production quality, and secures long-term contracts with global pharmaceutical companies. Lotte Biologics is adopting a dual-site strategy, leveraging its 40,000-litre facility in Syracuse, New York, in conjunction with the 120,000-litre plant in Songdo.

This approach allows the company to serve early development stages in the United States while handling large-scale commercial manufacturing in South Korea.

The restructuring of Lotte's business portfolio is aimed at creating a more resilient and diversified financial structure. By directing capital towards businesses with different cash generation cycles and investment payback periods, the group aims to manage its operations more effectively and reduce risk. However, this transformation is not without challenges.

Retail earnings remain vulnerable to consumer confidence and tourism trends, chemical profitability can be affected by market volatility and feedstock prices, and biologics development requires significant time and resources to achieve regulatory approval and commercial success.

In summary, Lotte's current strategy is focused on balancing the recovery of existing businesses with the development of new growth areas. The company is managing three distinct but interconnected business units, each with its own unique dynamics and timelines for profitability. While the immediate risks are evident, the long-term potential for Lotte Group lies in its ability to create a diversified, cash-generating portfolio that can adapt to changing market conditions.